Expansion and cytotoxicity of mucosal CAR+ T cells in enterocolitis associated with BCMA CAR-T cell therapy

Ciltacabtagene autoleucel (cilta-cel) is a B cell maturation-antigen-targeting chimeric antigen receptor (CAR) T cell product approved for relapsed/refractory multiple myeloma treatment. Previously reported cases of post-cilta-cel immune effector cell enterocolitis (IEC-EC) have been described as a severe diarrhea associated with clonal CAR T cell populations. Here we report nine cases of cilta-cel-associated IEC-EC with CAR T cell-positive (CAR + ) infiltration in 158 cilta-cel-treated patients at MD Anderson Cancer Center (incidence of 5.1% at a 6-month landmark and 5.7% globally). Cilta-cel infiltration was the primary cause of IEC-EC, and all cases demonstrated monoclonal or oligoclonal T cell populations as measured by vector integration analysis, flow cytometry and T cell receptor sequencing. Patients with IEC-EC had 100-fold more CAR T cell persistence in the peripheral blood than patients without IEC-EC. RNA sequencing analysis revealed increased cytotoxic and inflammatory programs associated with the CAR + infiltrates relative to controls. Clonal vector integration occurred in introns of highly expressed genes without evidence of vector-mediated mutagenesis. Candidate driver mutations were sparse and heterogeneous, distinguishing IEC-EC from peripheral T cell lymphoma following CAR T cell therapy. In sum, we find that IEC-EC pathology represents a distinct, duodenum-predominant, clonal lymphoproliferative disorder characterized by the infiltration of clonal CAR + cytotoxic T cells into the gastrointestinal tract.

Authors

Institutions

Publication Details

Journal
Nature Medicine
Published
2026-11-19
DOI
https://doi.org/10.1038/s41591-026-04731-w
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Expansion and cytotoxicity of mucosal CAR+ T cells in enterocolitis associated with BCMA CAR-T cell therapy

Mahmoud Gaballa, Francisco Vega, Sharlene Dong, Keyur Pravinchandra Patel et al.
Nature Medicine
CAR-T cell therapy research
article

Expansion and cytotoxicity of mucosal CAR+ T cells in enterocolitis associated with BCMA CAR-T cell therapy

Mahmoud Gaballa, Francisco Vega, Sharlene Dong, Keyur Pravinchandra Patel, Mark P. Hamilton, Christopher D. Pacheco, Surbhi Sidana, Lekha Mikkilineni, Paolo Strati, Robert Zygmunt Orlowski, Jared M. Henderson, Sairah Ahmed, David M. Richards, M R Green, Krina K. Patel, Bita Sahaf, Amy A. Ayers, Sattva Swarup Neelapu, Partow Kebriaei, Oren Pasvolsky, Wei‐Lien Wang, David Bernard Miklos, Christopher R. Flowers, Snehit Prabhu, Crystal Lee Mackall, Sa A. Wang, Aniruddha Mundhada, Hector J Garcia Pleitez, Francisco Cortina, Ziyi Li, Wei Wang, Yinghong Wang, Tania P. Sainz, Karmila Murphy, Xuehong Gui, Carla Villela, Swami P. Iyer
article en

Abstract

Ciltacabtagene autoleucel (cilta-cel) is a B cell maturation-antigen-targeting chimeric antigen receptor (CAR) T cell product approved for relapsed/refractory multiple myeloma treatment. Previously reported cases of post-cilta-cel immune effector cell enterocolitis (IEC-EC) have been described as a severe diarrhea associated with clonal CAR T cell populations. Here we report nine cases of cilta-cel-associated IEC-EC with CAR T cell-positive (CAR + ) infiltration in 158 cilta-cel-treated patients at MD Anderson Cancer Center (incidence of 5.1% at a 6-month landmark and 5.7% globally). Cilta-cel infiltration was the primary cause of IEC-EC, and all cases demonstrated monoclonal or oligoclonal T cell populations as measured by vector integration analysis, flow cytometry and T cell receptor sequencing. Patients with IEC-EC had 100-fold more CAR T cell persistence in the peripheral blood than patients without IEC-EC. RNA sequencing analysis revealed increased cytotoxic and inflammatory programs associated with the CAR + infiltrates relative to controls. Clonal vector integration occurred in introns of highly expressed genes without evidence of vector-mediated mutagenesis. Candidate driver mutations were sparse and heterogeneous, distinguishing IEC-EC from peripheral T cell lymphoma following CAR T cell therapy. In sum, we find that IEC-EC pathology represents a distinct, duodenum-predominant, clonal lymphoproliferative disorder characterized by the infiltration of clonal CAR + cytotoxic T cells into the gastrointestinal tract.

Nature Medicine
The University of Texas MD Anderson Cancer Center (US), Stanford Cancer Institute (US), Stanford University (US)
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon